ClinicalTrials.gg
CompletedNCT04840550Updated Sep 14, 2026

Study to Evaluate the Safety, Efficacy of Tegoprazan for the Prevention of PUD in Patients on Treatment With NSAIDs

A Phase 3 interventional study of Lansoprazole 15 mg and Tegoprazan 25 mg in Preventive Peptic Ulcer, sponsored by HK inno.N Corporation. Completed at 2 sites in South Korea. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by HK inno.N Corporation · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
392
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies in Peptic Ulcer with a site in Korea, Republic of — 4 open to participants now, 5 under way, 3 of them phase 3. Peptic Ulcer · Korea, Republic of.

Enrollment
6th of 16
392 · median 344
Started
2021
with 2 others
Phase 3
7 of 19
2 open now
Registered
15th of 19
by date
Lead sponsor
1 of 19
HK inno.N Corporation

Among the 19 studies in Peptic Ulcer with a site in Korea, Republic of, this one is the 6th largest by enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2021, is one of 7 in phase 3, and was the 15th registered.

Peptic Ulcer

146 studies on the registry are indexed under Peptic Ulcer; 25 are open to participants now.

Browse Peptic Ulcer studies →

Open to participants now

4 of the 19 studies in Peptic Ulcer with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 18 Peptic Ulcer studies recruiting now, 11 (61%) set no upper age limit and 7 (39%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Peptic Ulcer with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This study is designed to confirm the non-inferiority of Tegoprazan 25 mg, compared to Lansoprazole 15 mg, to prevent gastroduodenal ulcers and verify the safety of tegoprazan following oral administration of tegoprazan 25 mg QD or lansoprazole 15 mg QD in patients on long-term treatment with NSAIDs.

Read the detailed description

This is a double-blind, randomized, active-controlled, phase 3 study. Subjects will be randomly assigned to one of the two treatment groups (tegoprazan 25 mg, lansoprazole 15 mg).

03

Conditions studied

  • Preventive Peptic Ulcer

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥60 years of age, or ≥20 years of age with a history of gastroduodenal ulcers (gastric and/or duodenal ulcers) at screening
  • Requires continued treatment with NSAIDs for ≥24 weeks

Exclusion criteria

Exclusion Criteria:

  • Has an active stage (A1, A2) or healing stage (H1, H2) of gastroduodenal ulcers per the Sakita-Miwa classification identified by upper GI endoscopy at screening
  • Has uncontrolled severe hypertension
  • Has severe heart failure, congestive heart failure ( Ⅱ to Ⅳ), ischemic heart disease (unstable angina, myocardial infarction), or peripheral artery disease, or has undergone coronary artery bypass graft (CABG) who is considered ineligible for treatment with NSAIDs
  • Has a positive H. pylori test at screening
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
392 participants (actual)

Study arms

  • Experimental
    Tegoprazan 25mg

    Tegoprazan 25mg tablets will be orally administered once a day, with NSAIDs, for up to 6 months.

    Drug: Tegoprazan 25 mg

  • Active comparator
    Lansoprazole 15mg

    Lansoprazole 15mg capsules will be orally administered, once a day, with NSAIDs, for up to 6 months.

    Drug: Lansoprazole 15 mg

Interventions

  • Lansoprazole 15 mg tablets will be orally administered once a day, with NSAIDs, for up to 6 months.

  • Tegoprazan 25 mg tablets will be orally administered once a day, with NSAIDs, for up to 6 months.

06

What researchers measure

Primary outcomes

  1. Proportion of subjects with gastric and/or duodenal ulcers at Week 24

    The proportion of subjects with gastric and/or duodenal ulcers on upper GI endoscopy at Week 24

    Time frame: week 24

Secondary outcomes

  1. Proportion of subjects without NSAID-related GI symptoms at Weeks 4, 12, and 24

    GI symptoms are as follows; Heartburn, Regurgitation, Upper abdominal pain or discomfort

    Time frame: week 4, 12, 24

07

Study locations

2 sites
  • Samsung Medical Center
    Seoul, South Korea
  • The catholic univ. of Korea Eunpyeong ST. Mari's hospital
    Seoul, South Korea
08

References and documents

Publications

  • Kim SG, Kim TO, Jung SW, Min BH, Oh JH, Kim HS, Lee GH, Song JH, Sung IK, Cho YS, Choi SC, Lim YJ, Kim BW, Shin CM, Huh CW, Kim JW, Kim KO, Cho YK, Lee OY, Moon JS, Lee HW, Jung HY, Shin WG, Kim JG, Lee JY, Han SJ, Kim SW, Cho JH, Lim H, Kim TH, Park MI, Baik GH, Cha RR, Lee SK, Kim JJ. A Phase III, Randomized, Double-Blind, Active-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Tegoprazan for the Prevention of Peptic Ulcer in Patients on Continuous Long-Term Treatment with Nonsteroidal Anti-Inflammatory Drugs. Gut Liver. 2026 Jul 15;20(4):551-561. doi: 10.5009/gnl260057. Epub 2026 Jun 22. PubMed 42325011 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2021 to primary completion in Jul 2025, 49 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2021
First posted
Apr 12, 2021
StartActual
May 7, 2021
Primary completionActual
Jul 1, 2025
CompletionActual
Jul 1, 2025
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04840550
Responsible party
Sponsor
First posted
Apr 12, 2021
Start date
May 7, 2021
Primary completion
Jul 1, 2025
Completion
Jul 1, 2025
Last update
Sep 14, 2026

Study contacts

Jea Jun Kim
principal investigator · Samsung Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tegoprazan

Start the discussion